公司于2025年11月12日召开的2025年第一次临时股东大会审议通过了《关于变更注册资本、取消监事会 并修订公司章程的议案》，具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的公告。 根据2025年第一次临时股东大会的相关授权，公司向南京市市场监督管理局申请办理注册资本变更手 续。近日，公司已完成工商变更登记手续，并取得南京市市场监督管理局换发的《营业执照》。 证券代码：603707 证券简称：健友股份 公告编号：2026-004 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 关于完成工商变更登记的公告 变更后的《营业执照》基本信息如下： 1.统一社会信用代码：91320100726054999R 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 一般项目：采购代理服务；技术进出口；住房租赁；技术服务、技术开发、技术咨询、技术交流、技术 转让、技术推广；医学研究和试验发展；光伏发电设备租赁（除依法须经批准的项目外，凭营业执照依 法自主开展经营活动） 特此公告。 南京健友 ...

关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 证券代码：603707 | 证券简称：健友股份 公告编号：2026-004 | | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | 公司于 2025年11月12日召开的2025年第一次临时股东大会审议通过了《关 于变更注册资本、取消监事会并修订公司章程的议案》，具体内容详见公司在上 海证券交易所网站（www.sse.com.cn）披露的公告。根据 2025 年第一次临时股 东大会的相关授权，公司向南京市市场监督管理局申请办理注册资本变更手续。 近日，公司已完成工商变更登记手续，并取得南京市市场监督管理局换发的《营 业执照》。 南京健友生化制药股份有限公司 变更后的《营业执照》基本信息如下： 1.统一社会信用代码：91320100726054999R 2.名称：南京健友生化制药股份有限公司 特此公告。 3.类型：股份有限公司（上市、自然人投资或控股） 4.住所：南京高新开发区 MA010-1 号地 5.法定代表人 ...

Core Viewpoint - Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. plans to reverse inventory impairment provisions for the fiscal year 2025, which is expected to increase net profit attributable to shareholders by approximately 116 million to 174 million yuan [2][5]. Group 1: Inventory and Financial Impact - The company conducted a preliminary impairment test on inventory as of December 31, 2025, estimating a reversal of inventory impairment provisions between 137 million and 205 million yuan, which will positively impact net profit [2][5]. - The company's inventory balance at the end of each year from 2023 to 2025 was 5,405.50 million yuan, 4,429.84 million yuan, and 3,526.42 million yuan respectively, with the inventory primarily consisting of raw materials, finished goods, and work in progress [2][3]. - The reversal of inventory impairment provisions is based on the recovery of previously impaired inventory values, reflecting a more accurate financial position as of December 31, 2025 [4][5]. Group 2: Business Strategy and Future Plans - The company is transitioning from a single focus on standard heparin raw materials to a dual focus on both standard heparin raw materials and formulations, necessitating higher inventory levels [3]. - Future strategies include strengthening links with raw material buyers, maintaining stable sales of raw materials, and expanding the global market for heparin formulations [6]. - The company aims to increase sales of non-heparin formulations to enhance long-term competitiveness and generate stable operating cash flows [6].

南京健友生化制药股份有限公司 2025 年度拟转回存货跌价准备的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 南京健友生化制药股份有限公司（以下简称"公司"）根据《企业会计准则 第 1 号——存货》及公司会计政策等相关规定，对截至 2025 年 12 月 31 日存货 进行了初步减值测试，公司 2025 年度拟转回存货跌价准备 13,700.00 万元到 20,500.00 万元，预计导致归属于上市公司股东的净利润增加 11,600.00 万元到 17,400.00 万元。 本次拟转回存货跌价准备金额未经审计，最终会计处理及对公司 2025 年度 利润的影响以公司披露的 2025 年度报告为准。具体情况如下： | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 单位：万元、% 项目 2025 年末 2024 年末 2023 年末 金额 占比 金额 占比 金额 ...

Core Viewpoint - The company emphasizes the importance of market capitalization performance while acknowledging that daily market prices are influenced by multiple factors [1] Group 1: Company Focus - The company is committed to focusing on its mission, centering on patient needs through continuous innovation and high-quality operations to create value for society [1] - The company will adhere to principles of compliance, systematic approach, scientific methods, normalcy, and rationality in managing its market value [1] Group 2: Investor Relations - The company aims to provide solid operational performance and long-term value returns to its investors [1]

证券日报网讯1月23日，健友股份（603707）在互动平台回答投资者提问时表示，公司的本质是坚守使 命，以患者需求为核心，通过持续创新和稳健运营为社会创造价值。公司高度重视市值管理工作，始终 秉持合规、系统、科学、常态、理性的原则，致力于以扎实的经营业绩和长期价值回报每一位投资者。 公司会持续聚焦主业，通过不断推进研发管线、提升商业化能力来夯实内在价值。 ...

Group 1 - The core viewpoint of the news is that Jianyou Co., Ltd. has shown significant trading activity and financial performance indicators, with a notable increase in shareholder accounts and a decrease in revenue and net profit for the year 2025 [1][2]. Group 2 - On January 6, Jianyou Co., Ltd. experienced a stock price increase of 0.97%, with a trading volume of 95.34 million yuan. The financing buy-in amount for the day was 15.84 million yuan, while the net financing buy-in reached 3.83 million yuan [1]. - As of January 6, the total balance of margin trading for Jianyou Co., Ltd. was 279 million yuan, with the financing balance accounting for 1.83% of the circulating market value, indicating a high level compared to the past year [1]. - The company reported a total revenue of 2.926 billion yuan for the period from January to September 2025, reflecting a year-on-year decrease of 5.25%, while the net profit attributable to shareholders decreased by 29.11% to 429 million yuan [2]. - Jianyou Co., Ltd. has distributed a total of 1.198 billion yuan in dividends since its A-share listing, with 509 million yuan distributed over the past three years [3]. - As of September 30, 2025, the number of shareholders for Jianyou Co., Ltd. reached 38,000, an increase of 30.18%, while the average circulating shares per person decreased by 23.18% to 42,484 shares [2][3].

关于"健友转债"转股结果暨股份变动的公告 | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 根据有关规定和《南京健友生化制药股份有限公司公开发行可转换公司债券 募集说明书》的约定，公司该次发行的健友转债自 2020 年 10 月 29 日起可转换 为公司普通股股票，初始转股价格为 54.97 元/股。因公司实施 2020 年限制性股 票激励计划，自 2020 年 7 月 10 日起，健友转债转股价格变为 54.96 元/股。因 公司实施 2019 年年度权益分派，自 2020 年 7 月 23 日起，健友转债转股价格变 为 42.05 元/股。因公司实施 2021 年限制性股票激励计划，自 2021 年 6 月 25 日起，健友转债转股价格变为 42.01 元/股。因公司实施 2020 年年度权益分派， 自 2021 年 7 月 15 日起，健友转债转股价格变为 32.20 元/股。因公司实施 2021 年限制性股票激励计划预留授予，自 202 ...

Group 1 - The core point of the article is that Jianyou Co., Ltd. (603707.SH) has announced a share buyback program, having repurchased a total of 1.379995 million shares as of December 31, 2025, which represents 0.09% of the company's total share capital [1] - The minimum transaction price for the repurchased shares was 9.56 yuan per share, while the maximum transaction price reached 11.66 yuan per share [1] - The total amount paid for the share buyback was 15.0085 million yuan, excluding transaction fees and stamp duty [1]

Core Viewpoint - Jianyou Co., Ltd. (603707.SH) has announced a share buyback program, indicating a commitment to returning value to shareholders through capital management strategies [1] Group 1: Share Buyback Details - As of December 31, 2025, the company has repurchased a total of 1.379995 million shares [1] - The repurchased shares account for 0.09% of the company's total share capital [1] - The lowest transaction price during the buyback was 9.56 yuan per share, while the highest was 11.66 yuan per share [1] - The total amount paid for the buyback reached 15.0085 million yuan, excluding transaction fees and stamp duty [1]